Fig. 5.

Dynamic CT arterial phase images of the functional and structural changes of the TBV caused by the resumption of blood flow after dose reduction during lenvatinib treatment. a Case of a 77-year-old woman with HCC. The initial dose of lenvatinib was 8 mg. The blue bar indicates the dose of lenvatinib, and the yellow bar indicates the image-predicted tumor blood flow. Functional changes in the TBV caused the resumption of blood flow by dose reduction during lenvatinib treatment. Dynamic CT arterial phase images. b Case of a 65-year-old woman with HCC. The macroscopic TBV diameter shrank from 8 to 12 weeks. The yellow bar indicates the image-predicted tumor blood flow. Structural changes in the TBV for bulky HCC caused a marked shrinkage during lenvatinib treatment. Dynamic CT arterial phase images. Reprinted and modified with permission from Karger Publishers [14].